Dosing strategies for de novo once-daily extended release tacrolimus in kidney transplant recipients based on CYP3A5 genotype

Table 1 Baseline Characteristics (intent to treat population)

All patients (n = 36)
Age (yr), mean ± SD	55.5 ± 13.7
Male, n (%)	20 (55.6)
Race, n (%)
White	9 (25.0)
Black	24 (66.7)
Hispanic	2 (5.6)
Transplant type, n (%)
Deceased donor	25 (69.4)
Living donor	11 (30.6)
Hypertension, n (%)	28 (77.8)
Diabetes mellitus, n (%)	9 (25.0)
Focal segmental glomerulosclerosis, n (%)	1 (2.8)
Polycystic kidney disease, n (%)	1 (2.8)
HIV-associated nephropathy, n (%)	1 (2.8)
Lupus nephritis, n (%)	1 (2.8)
Transplant number, n (%)
One	35 (97.2)
Two	1 (2.8)
cPRA (%), median (IQR)	0 (0-10.0)
Actual body weight (kg), mean ± SD	87.4 ± 18.4
Dosing weight, n (%)
Actual	16 (44.4)
Adjusted	20 (55.6)
BMI (kg/m2), mean ± SD	30.0 ± 5.5

BMI: Body mass index; cPRA: Calculated panel reactive antibody; IQR: Interquartile range; HIV: Human immunodeficiency virus.